Фокальная лазерная терапия в дополнение к химиотерапии при ретинобластоме
References
References to studies excluded from this review
Jump to:
Additional references
Jump to:
Abramson DH, Frank CM, Susman M, Whalen MP, Dunkel IJ, Boyd NW. Presenting signs of retinoblastoma. Journal of Pediatrics 1998;132(3 Pt 1):505‐8.
Abramson DH, Schefler AC. Transpupillary thermotherapy as initial treatment for small intraocular retinoblastoma: technique and predictors of success. Ophthalmology 2004;111(5):984‐91.
Abramson DH, Melson MR, Servodidio C. Visual fields in retinoblastoma survivors. Archives of Ophthalmology 2004;122(9):1324‐30.
Abramson DH, Dunkel IJ, Brodie SE, Kim JW, Gobin YP. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology 2008;115(8):1398‐404.
Abramson DH, Shields CL, Munier FL, Chantada GL. Treatment of retinoblastoma in 2015: agreement and disagreement. JAMA Ophthalmology 2015;133(11):1341‐7.
Bowman RJ, Mafwiri M, Luthert P, Luande J, Wood M. Outcome of retinoblastoma in east Africa. Pediatric Blood and Cancer 2008;50(1):160‐2.
Brichard B, De Bruycker JJ, De Potter P, Neven B, Vermylen C, Cornu G. Combined chemotherapy and local treatment in the management of intraocular retinoblastoma. Medical and Pediatric Oncology 2002;38(6):411‐5.
Veritas Health Innovation. Covidence systematic review software. Version accessed prior to 18 April 2016. Melbourne: Veritas Health Innovation, 2015.
Da Silva VF, Raaphorst GP, Goyal R, Feeley M. Drug cytotoxicity at elevated temperature. In vitro study on the U‐87MG glioma cell line. Journal of Neurosurgery 1987;67(6):885‐8.
De Jong MC, Kors WA, De Graaf P, Castelijns JA, Moll AC, Kivelä T. The incidence of trilateral retinoblastoma: a systematic review and meta‐analysis. American Journal of Ophthalmology 2015;160(6):1116‐26.e.5.
Dimaras H, Kimani K, Dimba EA, Gronsdahl P, White A, Chan HS, et al. Retinoblastoma. Lancet 2012;379(9824):1436‐46.
Doz F, Neuenschwander S, Plantaz D, Courbon B, Gentet JC, Bouffet E, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Société Française d'Oncologie Pédiatrique. Journal of Clinical Oncology 1995;13(4):902‐9.
Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers M, Gorum T, et al. Preradiation intracarotid cisplatin treatment of newly diagnosed anaplastic gliomas. The CNS Cancer Consortium. Journal of Clinical Oncology 1992;10(3):452‐8.
Eng C, Li FP, Abramson DH, Ellsworth RM, Wong FL, Goldman MB, et al. Mortality from second tumors among long‐term survivors of retinoblastoma. Journal of the National Cancer Institute 1993;85(14):1121‐8.
Ericson LA, Rosengren BH. Present therapeutic resources in retinoblastoma. Acta Ophthalmologica 1961;39:569‐76.
Fletcher O, Easton D, Anderson K, Gilham C, Jay M, Peto J. Lifetime risks of common cancers among retinoblastoma survivors. Journal of the National Cancer Institute 2004;96(5):357‐63.
Follézou JY, Fauchon F, Chiras J. Intra‐arterial infusion of carboplatin in the treatment of malignant gliomas: a phase II study. Neoplasma 1989;36(3):349‐52.
Gallie BL, Budning A, DeBoer G, Thiessen JJ, Koren G, Verjee Z, et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Archives of Ophthalmology 1996;114(11):1321‐8.
Gaynon PS. Carboplatin in pediatric malignancies. Seminars in Oncology 1994;21(5 Suppl 12):65‐76.
Glanville JM, Lefebvre C, Miles JN, Camosso‐Stefinovic J. How to identify randomized controlled trials in MEDLINE: ten years on. Journal of the Medical Library Association 2006;94(2):130‐6.
Gombos DS, Kelly A, Coen PG, Kingston JE, Hungerford JL. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. British Journal of Ophthalmology 2002;86(1):80‐3.
Gombos DS, Cauchi PA, Hungerford JL, Addison P, Coen PG, Kingston JE. Vitreous relapse following primary chemotherapy for retinoblastoma: is adjuvant diode laser a risk factor?. British Journal of Ophthalmology 2006;90(9):1168‐72.
Gombos DS, Hungerford J, Abramson DH, Kingston J, Chantada G, Dunkel IJ, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor?. Ophthalmology 2007;114(7):1378‐83.
GRADE Working Group, McMaster University. GRADEpro GDT. Version accessed 18 April 2016. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Harbour JW, Murray TG, Hamasaki D, Cicciarelli N, Hernández E, Smith B, et al. Local carboplatin therapy in transgenic murine retinoblastoma. Investigative Ophthalmology and Visual Science 1996;37(9):1892‐8.
Herman TS, Teicher BA. Summary of studies adding systemic chemotherapy to local hyperthermia and radiation. International Journal of Hyperthermia 1994;10(3):443‐9.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327:557‐60.
Higgins JP, Altman DG, Sterne JAC, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Kaneko A, Suzuki S. Eye‐preservation treatment of retinoblastoma with vitreous seeding. Japanese Journal of Clinical Oncology 2003;33(12):601‐7.
Khelfaoui F, Validire P, Auperin A, Quintana E, Michon J, Pacquement H, et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996;77(6):1206‐13.
Kingston JE, Hungerford JL, Madreperla SA, Plowman PN. Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Archives of Ophthalmology 1996;114(11):1339‐43.
Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. British Journal of Ophthalmology2009; Vol. 93, issue 9:1129‐31.
Kleinerman RA, Tucker MA, Tarone RE, Abramson DH, Seddon JM, Stovall M, et al. Risk of new cancers after radiotherapy in long‐term survivors of retinoblastoma: an extended follow‐up. Journal of Clinical Oncology 2005;23(10):2272‐9.
Knudson AG. Mutation and cancer: statistical study of retinoblastoma. Proceedings of the National Academy of Sciences 1971;68(4):820‐3.
Kupfer C. Retinoblastoma treated with intravenous nitrogen mustard. American Journal of Ophthalmology 1953;36(12):1721‐3.
Lagendijk JJ. A microwave heating technique for the hyperthermic treatment of tumours in the eye, especially retinoblastoma. Physics in Medicine and Biology 1982;27(11):1313‐24.
Lambert MP, Shields C, Meadows AT. A retrospective review of hearing in children with retinoblastoma treated with carboplatin‐based chemotherapy. Pediatric Blood and Cancer 2008;50(2):223‐6.
Larner JM, Phillips CD, Dion JE, Jensen ME, Newman SA, Jane JA. A phase 1‐2 trial of superselective carboplatin, low‐dose infusional 5‐fluorouracil and concurrent radiation for high‐grade gliomas. American Journal of Clinical Oncology 1995;18(1):1‐7.
Lee TC, Lee SW, Dinkin MJ, Ober MD, Beaverson KL, Abramson DH. Chorioretinal scar growth after 810‐nanometer laser treatment for retinoblastoma. Ophthalmology 2004;111(5):992‐6.
Lumbroso L, Doz F, Urbieta M, Levy C, Bours D, Asselain B, et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology 2002;109(6):1130‐6.
MacCarthy A, Birch JM, Draper GJ, Hungerford JL, Kingston JE, Kroll ME, et al. Retinoblastoma in Great Britain 1963‐2002. British Journal of Ophthalmology 2009;93(1):33‐7.
Menon BS, Alagaratnam J, Juraida E, Mohamed M, Ibrahim H, Naing NN. Late presentation of retinoblastoma in Malaysia. Pediatric Blood and Cancer 2009;52(2):215‐7.
Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta‐Analyses: The PRISMA Statement. PLoS Medicine 2009;6(7):e1000097. [DOI: 10.1371/journal.pmed1000097]
Munier FL, Gaillard MC, Balmer A, Soliman S, Podilsky G, Moulin AP, et al. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. British Journal of Ophthalmology 2012;96(8):1078‐83.
Murphree AL, Villablanca JG, Deegan WF, Sato JK, Malogolowkin M, Fisher A, et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Archives of Ophthalmology 1996;114(11):1348‐56.
Murphree LA. Intraocular retinoblastoma: the case for a new group classification. Ophthalmology Clinics of North America 2005;18(1):45‐53.
Murray TG, Cicciarelli N, McCabe CM, Ksander B, Feuer W, Schiffman J, et al. In vitro efficacy of carboplatin and hyperthermia in a murine retinoblastoma cell line. Investigative Ophthalmology and Visual Science 1997;38(12):2516‐22.
Novetsky DE, Abramson DH, Kim JW, Dunkel IJ. Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies‐‐an analysis of impact. Ophthalmic Genetics 2009;30(1):40‐4.
Reese AB, Merriam GR, Martin HE. Treatment of bilateral retinoblastoma by irradiation and surgery; report on 15‐year results. American Journal of Ophthalmology 1949;32(2):175‐90.
Reese AB, Hyman GA, Tapley ND, Forrest AW. The treatment of retinoblastoma by X‐ray and triethylene melamine. AMA Archives of Ophthalmology 1958;60(5):897‐906.
Reese AB, Ellsworth RM. Management of retinoblastoma. Annals of the New York Academy of Sciences 1964;114(2):958‐62.
Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Riccardi R, Riccardi A, Di Rocco C, Carelli G, Tartaglia RL, Lasorella A, et al. Cerebrospinal fluid pharmacokinetics of carboplatin in children with brain tumors. Cancer Chemotherapy and Pharmacology 1992;30(1):21‐4.
Schefler AC, Cicciarelli N, Feuer W, Toledano S, Murray TG. Macular retinoblastoma: evaluation of tumor control, local complications, and visual outcomes for eyes treated with chemotherapy and repetitive foveal laser ablation. Ophthalmology 2007;114(1):162‐9.
Seregard S, Kock E, af Trampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye. British Journal of Ophthalmology 1995;79(2):194‐5.
Shields CL, De Potter P, Himelstein BP, Shields JA, Meadows AT, Maris JM. Chemoreduction in the initial management of intraocular retinoblastoma. Archives of Ophthalmology 1996;114(11):1330‐8.
Shields CL, Santos MC, Diniz W, Gündüz K, Mercado G, Cater JR, et al. Thermotherapy for retinoblastoma. Archives of Ophthalmology 1999;117(7):885‐93.
Shields CL, Honavar SG, Meadows AT, Shields JA, Demirci H, Singh A, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. American Journal of Ophthalmology 2002;133(5):657‐64.
Shields CL, Meadows AT, Leahey AM, Shields JA. Continuing challenges in the management of retinoblastoma with chemotherapy. Retina 2004;24(6):849‐62.
Shields CL, Mashayekhi A, Cater J, Shelil A, Ness S, Meadows AT, et al. Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Archives of Ophthalmology 2005;123(6):765‐73.
Stallard HB. Irradiation of retinoblastoma (glioma retinae). Lancet 1952;1(6717):1046‐9.
Tapazoglou E, Cohen JD, Schmitt CL, Khatana A, Sapareto SA, Robins HI. Whole body hyperthermia and carboplatin: cytotoxicity for murine leukaemia and normal marrow. British Journal of Cancer 1991;64(3):528‐30.
Turaka K, Shields CL, Meadows AT, Leahey A. Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatric Blood and Cancer 2012;59(1):121‐5.
White L. The role of chemotherapy in the treatment of retinoblastoma. Retina 1983;3(3):194‐9.
Wilson MW, Rodriguez‐Galindo C, Haik BG, Moshfeghi DM, Merchant TE, Pratt CB. Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001;108(11):2106‐14.
Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma. International Journal of Clinical Oncology 2004;9(2):69‐73.
Characteristics of studies
Characteristics of excluded studies [ordered by study ID]
| Study | Reason for exclusion |
| Prospective but non‐randomised single‐arm clinical trial | |
| Comparative study in which cohort 1 consisted of participants treated with intravenous etoposide and carboplatin only and cohort 2 consisted of participants treated similarly to cohort 1 followed by intravenous carboplatin in conjunction with diode laser. No randomisation | |
| Randomised study comparing participants receiving intravenous vincristine and carboplatin versus etoposide and carboplatin. Following chemotherapy, participants also received laser therapy, among other treatments, at the discretion of the treating clinician. However, adjuvant therapy was given in a non‐randomised fashion. | |
| A prospective but non‐randomised clinical trial comparing participants treated with intravenous vincristine, etoposide and carboplatin with/without adjuvant treatments (i.e. diode laser and other modalities) |
